WHO ICTRP trial
Reduction or discontinuation of tofacitinib in patients with rheumatoid…
ChiCTR2000039799 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000039799 |
|---|---|
| Public title | Reduction or discontinuation of tofacitinib in patients with rheumatoid arthritis after low disease activity: a multicenter, prospective study |
| Scientific title | Reduction or discontinuation of tofacitinib in patients with rheumatoid arthritis after low disease activity: a multicenter, prospective study |
| Primary sponsor | Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Rheumatoid Arthritis |
| Interventions | A:Keep the dose of tofacitinib unchanged;B:Reduce the dose of tofacitinib to 5mg qd;C:Stop using tofacitinib |
| Registration date | Nov 10, 2020 |
| Target size | A:42;B:42;C:42 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: